Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951553 | 0.95 | PDCD1 (0.34) | PDCD1CD274CHRNB2CHRNA4 | |
| SCHEMBL20496069 | 0.87 | PDCD1 (0.31) | PDCD1CD274CHRNB2CHRNA4 | |
| SCHEMBL27493379 | 0.86 | PDCD1 (0.34) | PDCD1CD274CHRNB2CHRNA4 | |
| SCHEMBL29216495 | 0.86 | — | — | |
| SCHEMBL7604235 | 0.82 | PDCD1 (0.35) | PDCD1CD274CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL7636569 | 0.82 | PDCD1 (0.32) | PDCD1CD274CHRNB2CHRNA4 | |
| SCHEMBL7643009 | 0.82 | BRD4 (0.33) | PDCD1CD274CHRNB2CHRNA4 | |
| SCHEMBL7636072 | 0.82 | BRD4 (0.33) | PDCD1CD274CHRNB2CHRNA4 | |
| SCHEMBL2525984 | 0.82 | PDCD1 (0.33) | PDCD1CD274CHRNB2CHRNA4 | |
| Ethane SCHEMBL8631874 | 0.81 | PDCD1 (0.31) | PDCD1CD274CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021194831-A1 | ALKYLATION OF TRANSITION METAL COORDINATION CATALYST COMPLEXES | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-09-30 | — | — | WO | claimed |
| WO-2021194831-A1 | ALKYLATION OF TRANSITION METAL COORDINATION CATALYST COMPLEXES | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-10280240-B2 | Metallocene catalyst compositions and polymerization process therewith | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170342175-A1 | Metallocene Catalyst Compositions and Polymerization Process Therewith | EXXONMOBIL CHEMICAL PATENTS INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280240-B2 | Metallocene catalyst compositions and polymerization process therewith | TERT, TERB1, PARG | PDCD1 722/4885CD274 1036/4885CHRNB2 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.